Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

Jeremy D. Rubinstein; Adam S. Nelson; Christa Krupski; William O'Brien; J. Michael Taylor; Tom C. Badgett; Michael Huang; Stella M. Davies; Christine L. Phillips

doi:10.1002/pbc.28199

Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

Jeremy D. Rubinstein, Adam S. Nelson, Christa Krupski, William O'Brien, J. Michael Taylor, Tom C. Badgett, Michael Huang, Stella M. Davies, Christine L. Phillips

Division of Hematology & Oncology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

Original language	English
Article number	e28199
Journal	Pediatric Blood and Cancer
Volume	67
Issue number	4
DOIs	https://doi.org/10.1002/pbc.28199
State	Published - Apr 1 2020

Keywords

CAR-T
cellular therapy
neurotoxicity
pre-B ALL

Access to Document

10.1002/pbc.28199

Cite this

@article{bd5a9fc233634b3fbeb70c54edcf1807,

title = "Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities",

abstract = "Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.",

keywords = "CAR-T, cellular therapy, neurotoxicity, pre-B ALL",

author = "Rubinstein, {Jeremy D.} and Nelson, {Adam S.} and Christa Krupski and William O'Brien and Taylor, {J. Michael} and Badgett, {Tom C.} and Michael Huang and Davies, {Stella M.} and Phillips, {Christine L.}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",

year = "2020",

month = apr,

day = "1",

doi = "10.1002/pbc.28199",

language = "English",

volume = "67",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "4",

}

TY - JOUR

T1 - Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

AU - Rubinstein, Jeremy D.

AU - Nelson, Adam S.

AU - Krupski, Christa

AU - O'Brien, William

AU - Taylor, J. Michael

AU - Badgett, Tom C.

AU - Huang, Michael

AU - Davies, Stella M.

AU - Phillips, Christine L.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

AB - Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

KW - CAR-T

KW - cellular therapy

KW - neurotoxicity

KW - pre-B ALL

UR - http://www.scopus.com/inward/record.url?scp=85079051552&partnerID=8YFLogxK

U2 - 10.1002/pbc.28199

DO - 10.1002/pbc.28199

M3 - Article

C2 - 32020723

AN - SCOPUS:85079051552

SN - 1545-5009

VL - 67

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

M1 - e28199

ER -

Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this